Danielle Ternyila

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.

Cristina Gasparetto, MD, discusses the combination of daratumumab, selinexor, and dexamethasone in patients with multiple myeloma who have previously received ≥3 lines of therapy, which include an immunomodulatory agent and a proteasome inhibitor.

Five leaders in the fight against gastrointestinal cancers from academia, the community, and clinic were honored at the 2018 Luminary Awards.

William J. Gradishar, MD, discusses how far the breast cancer field has advanced over the last 20 years and the data he is anticipating to read out in the future.

Andrea V. Barrio, MD, discusses the challenges with phyllodes tumors of the breast and how to manage this disease moving forward.

Monica Morrow, MD, addresses how she treats patients with breast cancer who have locoregional recurrence and how therapeutic approaches have evolved over recent years.

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.